Study of Systemic Treatments and ctDNA Testing to Monitor Response in Patients with Metastatic Cancer Using K4Care

What this Trial Is About

Researchers are investigating the treatment landscape for patients with metastatic cancer, focusing on the role of circulating tumor DNA ctDNA in monitoring how these patients respond to their treatments. This observational, prospective, and longitudinal study collects data from patients who have undergone K4Care testing between March 2025 and March 2026. The study aims to better understand how ctDNA levels relate to cancer progression and treatment effectiveness. Participants will have two blood samples collectedone at enrollment and another during a follow-up visit 3 to 6 months later or as per the participants follow-up schedule. Clinical information including demographics, medical history, cancer diagnosis details, treatment regimens like surgery or chemotherapy, and imaging results will be gathered from patient records. The study also records important clinical outcomes such as tumor response, progression, and survival status. During the study, researchers will assess ctDNA clearance and its correlation with treatment response over 18 months. Patient assessments involve imaging like CT or MRI scans, physician evaluations of disease status, and collection of blood samples for ctDNA analysis. The study monitors progression-free survival and overall survival while collecting comprehensive clinical and pathological data to understand the relationship between ctDNA and cancer treatment outcomes.

Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.